Drapkin Kimberlee C 4

What Happened
Kimberlee C. Drapkin, a director of Climb Bio, received a grant of 40,000 derivative shares (reported acquisition price $0) on June 5, 2026. The filing reports this as an award/acquisition (code A). No cash changed hands in the filing; the award carries a vesting condition described in the footnote.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 8, 2026 (within the usual two-business-day reporting window).
• Amount: 40,000 derivative shares; reported price/acquisition amount: $0; total reported value: $0.
• Shares owned after transaction: Not specified in this filing.
• Footnote: The shares will vest on the earlier of June 5, 2027 or immediately prior to the next annual meeting of stockholders, subject to Drapkin’s continued service through that date.
• Exhibit: 24.1 (Power of Attorney) included with the filing.

Context
This was an equity award to a director (not a purchase or a sale). Derivative grants like this typically vest over time and do not indicate an immediate sale or cashless exercise. For retail investors, awards are routine for director compensation; they signal alignment with shareholder interests but are not a direct market bet.